Objectives: Poor cell survival severely limits the beneficial effect of adipose-derived stem cell (ADSC)-based therapy for disease treatment and tissue regeneration, which might be caused by the attenuated level of hypoxia-inducible factor-1 (HIF-1) in these cells after having been cultured in 21% ambient oxygen in vitro for weeks. In this study, we explored the role of pre-incubation in dimethyloxalylglycine (DMOG, HIF-1 activator) in the survivability of human ADSCs in a simulated ischaemic microenvironment in vitro and in vivo. The underlying mechanism and angiogenesis were also studied. 
| INTRODUCTION
As a type of regenerative medicine, stem cell therapy can be applied to substitute or restore injured tissue and cells to treat diseases. 1 Fat tissue has been proven as an abundant autologous source of adipose-derived stem cells (ADSCs) as defined by the International Society of Cellular Therapy (ISCT) and International Federation for Adipose Therapeutics and Science (IFATS). 2 These cells can be safely harvested through minimally invasive liposuction and have a similar therapeutic potential to other types of mesenchymal stem cells. 3 As a result, ADSC-based therapy is currently undergoing clinical trial in a number of diseases including diabetes, ischaemia and Parkinson's disease, among others, according to the database of clinicaltrials.gov and is also being used in preclinical studies of urethral structure 4 and adipose regeneration. 5 However, there are still critical challenges to overcome. Low survival rate of cells after transplantation have attracted substantial attention, 6 and enhancing the survivability of transplanted ADSCs is critical for improving the prognosis of ADSC-based therapy.
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During the initial periods of cell therapy, transplanted ADSCs must survive in an ischaemic microenvironment characterized by low oxygen, glucose and pH, which is the dominating cause of cell death. 7 The expression of hypoxia-inducible factor 1 (HIF-1) by cells in an ischaemic environment provides a potential strategy to improve cell therapeutic outcomes. HIF-1 is a heterodimer composed by O 2 -antagonistic HIF-1α and constitutively expressed HIF-1β subunits. 8 HIF-1α is subjected to prolyl hydroxylation (PHD) in the presence of O 2 , which results in its ubiquitination and proteasomal degradation. This hydroxylation is inhibited under hypoxia and gives rise to the accumulation of HIF-1α.
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Prolyl hydroxylase inhibitors, such as dimethyloxalylglycine (DMOG), can simulate this suppression leading to HIF-1 activation under normoxia.
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HIF-1 activates the transcription of diverse genes encoding angiogenic cytokines, including vascular endothelial growth factor (VEGF), stromal-derived factor 1 (SDF-1), placental growth factor (PLGF), angiopoietin 1 and 2, and platelet-derived growth factor B, [10] [11] [12] [13] [14] which can improve vascularization for cell therapy.
Metabolic reprogramming, a suite of metabolic alterations as a result of HIF-1 that maintain homeostasis of energy, glucose and pH, may be an effective way of increasing cell survival in the ischaemic microenvironment after ADSC transplantation. First, HIF-1 activates glutaminase-regulated glutathione synthesis, retaining redox homeostasis at baseline when faced with oxidative or nutrient stress. 15 Second, HIF-1 signalling increases the glycogen reserve in preparation for an energy deficit during nutrient or oxygen depletion. 16 Third, HIF-1 reduces the production of reactive oxygen species (ROS) under hypoxia by increasing the efficiency of respiration, inactivating pyruvate dehydrogenase and triggering selective mitophagy. [17] [18] [19] [20] Fourth, HIF-1 augments glucose uptake and flux from glucose to lactate. [21] [22] [23] Fifth, HIF-1 maintains the intracellular pH by exporting H + as well as lactate. 24, 25 DMOG has the capacity of activating HIF-1 signalling and has the potential to promote cell survival and angiogenesis in cell therapy.
Some researchers have already employed HIF-1 to improve cells of the brain, 26,27 heart 28,29 and kidney 30 in preclinical ischaemic-disease models and bone regeneration 31 in mouse models. These beneficial results provide a sound foundation for ADSC-based therapy.
The aim of this study was to investigate whether and how DMOGinduced metabolic reprogramming increases ADSC survival and angiogenesis using an ischaemic cell culture model and subcutaneously implanted ADSCs into nude mice after being combined with fibrin gel. We demonstrate that stabilization of HIF-1 in ADSCs prior to implantation results in metabolic reprogramming and improves cell survival and angiogenesis.
| MATERIALS AND METHODS

| Cell isolation and DMOG preconditioning
Cells were isolated from subcutaneous adipose tissues harvested from the abdomen of females who underwent liposuction, and informed consent was obtained. The adipose tissues were digested with 0.2% collagenase (Sigma-Aldrich, St. Louis, MO, USA)/phosphate-buffered saline (PBS), and then the mixture was transferred into a 37°C water bath for 40 minutes. After centrifugation at 1,000 rpm for 5 minutes, the supernatant was removed. The remaining cellular pellet was resuspended in PBS and centrifuged at 1,000 rpm for 5 minutes. After discarding the supernatant, the remaining cells were cultured with α- was used to perform the analysis.
| Flow cytometry
| Western blotting
Western blot was conducted as previously described. 32 In brief, cell pellets were dissolved in radio immunoprecipitation assay (RIPA) buffer (KeyGEN, Nanjing, China) immediately after discarding the DMOG or vehicle-added medium and 30 μg cell protein was separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).
The proteins were blotted onto polyvinylidene fluoride (PVDF) mem- 
| Cell counting kit-8 (CCK-8)
CCK-8 (Dojindo, Japan) dye solution (90 μL of α-MEM with 10 μL
CCK-8) was added in each well (1×10 4 cells, 96-well plates). Wells
containing α-MEM without cells were used as blanks. After incubation at 37°C for 2 hours, the samples were taken out, and absorbance was detected at 450 nm using a spectrophotometer (Multiskan GO;
Thermo Scientific). The results were calculated according to the for-
| Real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated using RNAiso Plus (TaKaRa Biotechnology, Table S1 .
| Measurement of mitochondrial mass, ROS and glucose uptake
Mitochondrial mass, mitochondrial or cytosolic ROS levels and glucose uptake were determined by staining cells with 10 nmol/L nonyl acridine orange (NAO; Sigma-Aldrich), 5 μmol/L MitoSOX™ RED (Life
Life Technologies), respectively, at 37°C for 30 minutes. Cells were analysed immediately with a fluorescence microscope (Olympus) and BD Accuri™ C6 (BD Biosciences) with a minimum of 5,000 events acquired per sample.
| Glycogen staining
Periodic acid-Schiff (PAS) staining was used to visualize glycogen in cells. ADSCs on coverslips were fixed in 4% paraformaldehyde and incubated in 0.5% periodic acid (Solarbio) for 5 minutes. Then, cells
were washed in distilled water for 5 minutes and treated with Schiff's reagent (Solarbio) for 15 minutes. After washing with distilled water for 5 minutes, the cells were dehydrated and mounted.
| Intracellular pH measurements
Intracellular pH was measured using Multimode Reader (Thermo 
| Extracellular lactate measurements
Lactate content of the ADSC culture media was assayed using a lactate assay kit (KeyGEN) according to the manufacturer's instructions.
| Tube formation assay
Fifty microlitres of Matrigel (Corning, NY, USA) was added to each well of a 96-well plate and incubated at 37°C for 30 minutes. ADSCs (2×10 4 cells) were seeded into the coated wells. After incubation at 37°C for 6 hours, tube formation was visualized under a microscope (Olympus).
Images were analysed using Wimasis Image Analysis software (Ibidi, Martinsried, Germany).
| In vivo study
Preparation of fibrin gel: Fibrin gel was prepared as previously de- and 150 μmol/L) (E) to determine an optimal condition. Western blotting showed higher HIF-1 protein expression (F) in ADSCs treated with 100 μmol/L DMOG for 4 days, which exhibited the best stimulation effect in D and E. *P<.05, **P <.01, scale bar=50 μm
| Statistical analysis
Each experiment was repeated at least three times. The data were collected and expressed as the mean±standard deviation. Statistical analysis using GraphPad Prism 5.02 (GraphPad Software, San Diego, CA, USA) was performed with unpaired Student's t tests. Two-sided P<0.05 was considered statistically significant.
| RESULTS
| Characterization of ADSCs
Cell surface marker characterization using flow cytometry indicated that ADSCs expressed CD73, CD90 and CD105 and were negative for CD31, CD34 or HLA-DR ( Figure 1A) . ADSCs displayed the presence 
| Optimal concentration and duration of DMOG preconditioning
After treating ADSCs with DMOG at several concentrations (50, 100 and 150 μmol/L) ( Figure 1D ) and for various time periods (2, 4 and 7 days) ( Figure 1E ), the mRNA expression levels of three HIF-1 target genes (COX4I2, NHE2 and CAR9) were detected by RT-PCR using cultured ADSCs in the presence of vehicle as the control group.
Compared to the other conditions, the group with 100 μmol/L of DMOG for 4 days showed an optimal effect of HIF-1 signalling, and under this condition, the protein level of HIF-1 displayed an apparent increase from the results of Western blotting ( Figure 1F ).
| Increased survival of DMOG-preconditioned ADSCs in the ischaemic model
When ADSCs are transplanted in vivo, they encounter an ischaemic environment which is acidic, hypoxic and nutrient-depleted. Using an ischaemic model that mimicked above-mentioned features, we found that compared with vehicle-preconditioned ADSCs, DMOG- 
Statistical analysis of live/dead assay results was performed using
ImageJ and is shown in Figure 2H (*P<.05, **P<.01).
| Alteration of energy and pH metabolism in D-ADSCs
Next, we explored the metabolic alterations caused by DMOG preconditioning, and an approximately 50% decrease of mitochondrial mass was measured by staining with nonyl acridine orange, which binds to cardiolipin in mitochondrial membranes, in D-ADSCs (NHE2, NHE3 and CAR9 respectively) was significantly increased in D-ADSCs ( Figure 3E ). 
| Alteration of glycolytic metabolism in D-ADSCs
| Enhanced angiogenic activities of D-ADSCs in vitro
The consequence of DMOG preconditioning on angiogenesis of
ADSCs was detected by tube formation assay. In spite of the ability 
| Enhanced survival of D-ADSCs in vivo
Implantation of D-ADSCs with fibrin gel significantly promoted in vivo survival of these cells in mice measured by TUNEL assay ( Figure 6A )
and BrdU-labelling ( Figure 6D ). For TUNEL assay, cell death was distinguished by the ratio of TUNEL-positive cells vs total cells. In the V-ADSCs group, 57.0±5.0%, 58.4±3.4% and 60.4±9.5% of total im- and 72 hours, respectively). The colour variation of ELISA in Figure 6D illustrates the impact of DMOG on the survival of implanted ADSCs.
| DISCUSSION
The poor survival of engrafted cells in relatively ischaemic areas significantly affects the effectiveness of cell therapy. 6 To improve this situation, DMOG, a PHD inhibitor, was used to pre-treat ADSCs, and the present study demonstrates for the first time, to the best of our 
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When ADSCs encounter initial stages of ischaemia, they require the reestablishment of blood supply, which explains the significance of angiogenesis. We probed this capacity, and discovered an obvious promotion, indicating that DMOG treatment may be conducive to angiogenesis of ADSCs in cell therapy.
A notable drawback of cell therapy is the risk of tumorigeneses.
Indeed, PHD inhibitors may provide an appropriate environment for tumour growth and metastasis by stabilizing HIF-1, which plays a major role in tumorigenesis. 1 However, preconditioning approaches usually regulate correlative genes over a relatively short term (within 1 week) 37 ; this strategy might therefore not be accompanied by the risk of tumorigenesis. Moreover, some studies have dispelled this doubt.
The transition of glutamine, which controls cell survival and proliferation, to glutathione in hypoxic cancer cells differs from the application of glutamine in skeletal progenitor cells. 
